Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma.
Zare H, Bashashati A, Kridel R, Aghaeepour N, Haffari G, Connors JM, Gascoyne RD, Gupta A, Brinkman RR, Weng AP.
Am J Clin Pathol. 2012 Jan;137(1):75-85.
Related citations
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series.
Ryan RJ, Sloan JM, Collins AB, Mansouri J, Raje NS, Zukerberg LR, Ferry JA.
Am J Clin Pathol. 2012 Jan;137(1):51-64.
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S.
Am J Hematol. 2012 Mar;87(3):277-83. doi: 10.1002/ajh.22263. Epub 2011 Dec 21.
Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell lymphoma.
Stephen S, Morrissey KA, Benoit BM, Kim EJ, Vittorio CC, Nasta SD, Showe LC, Wysocka M, Rook AH.
Am J Hematol. 2011 Oct 23. doi: 10.1002/ajh.22231. [Epub ahead of print] No abstract available.
Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.
O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L.
Blood. 2012 Feb 16;119(7):1717-25. Epub 2011 Dec 20.
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, Horwitz S, Moskowitz AJ, Noy A, Palomba L, Perales MA, Portlock C, Straus D, Maragulia JC, Schoder H, Yahalom J.
Blood. 2012 Feb 16;119(7):1665-70. Epub 2011 Dec 19.
ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.
Calpe E, Codony C, Baptista MJ, Abrisqueta P, Carpio C, Purroy N, Bosch F, Crespo M.
Blood. 2011 Oct 20;118(16):4401-10. Epub 2011 Aug 24.
Racial patterns of extranodal natural killer/T-cell lymphoma, nasal type, in California: a population-based study.
Ai WZ, Chang ET, Fish K, Fu K, Weisenburger DD, Keegan TH.
Br J Haematol. 2012 Mar;156(5):626-32. doi: 10.1111/j.1365-2141.2011.08982.x. Epub 2011 Dec 20.
Management of children with high-risk Hodgkin lymphoma.
Kelly KM.
Br J Haematol. 2011 Dec 20. doi: 10.1111/j.1365-2141.2011.08975.x. [Epub ahead of print]
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy A.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26731. [Epub ahead of print]
Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26723. [Epub ahead of print]
Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26709. [Epub ahead of print]
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: Phase 2 study of the Italian Lymphoma Foundation.
Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L.
Cancer. 2011 Dec 16. doi: 10.1002/cncr.26708. [Epub ahead of print]
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
Villa D, Seshadri T, Puig N, Massey C, Tsang R, Keating A, Crump M, Kuruvilla J.
Haematologica. 2012 May;97(5):751-7. Epub 2011 Dec 16.
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma.
Xu C, Plattel W, van den Berg A, Rüther N, Huang X, Wang M, de Jong D, Vos H, van Imhoff G, Viardot A, Möller P, Poppema S, Diepstra A, Visser L.
Haematologica. 2012 Apr;97(4):572-8. Epub 2011 Dec 16.
Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma.
Jonak C, Troch M, Kiesewetter B, Lukas J, Müllauer L, Jäger U, Chott A, Raderer M.
Haematologica. 2012 May;97(5):766-70. Epub 2011 Dec 16.
Bfl-1 is a crucial pro-survival nuclear factor-κB target gene in Hodgkin/Reed-Sternberg cells.
Loughran ST, Campion EM, D'Souza BN, Smith SM, Vrzalikova K, Wen K, Murray PG, Walls D.
Int J Cancer. 2011 Dec 15;129(12):2787-96. doi: 10.1002/ijc.25950. Epub 2011 Apr 13.
Response to "Role of FDG-PET in the definition and management of involved-field radiation therapy for pediatric Hodgkin's lymphoma."Int J Radiat Oncol Biol Phys (2011;80:324-332).
Wang J, Shi M.
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):494; author reply 494. No abstract available.
Concordant and discordant bone marrow involvement in diffuse large B-cell lymphoma: are they understudied phenomena?
Wannesson L, Chigrinova E.
J Clin Oncol. 2012 Jan 20;30(3):336; author reply 336-7. Epub 2011 Dec 19. No abstract available.
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.
van Gaal JC, Flucke UE, Roeffen MH, de Bont ES, Sleijfer S, Mavinkurve-Groothuis AM, Suurmeijer AJ, van der Graaf WT, Versleijen-Jonkers YM.
J Clin Oncol. 2012 Jan 20;30(3):308-15. Epub 2011 Dec 19.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on